董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Isaac Israel | 男 | Director | 47 | 未披露 | 0.06 | 2026-09-18 |
| Udi Gilboa | 男 | Executive Chairman of the Board | 59 | 54.51万美元 | 194.24 | 2026-09-18 |
| David Silberman | 男 | Director | 42 | 未披露 | 0.06 | 2026-09-18 |
| Ronnie Hershman | 男 | Director | 67 | 未披露 | 141.95 | 2026-09-18 |
| Brendan P. O'Grady | 男 | Chief Executive Officer and Director | -- | 未披露 | 未持股 | 2026-09-18 |
| Dalia Megiddo | 女 | Chief Development Officer and Chief Medical Officer and Director | 74 | 48.83万美元 | 189.41 | 2026-09-18 |
| Sharon Shacham | 女 | Director | 55 | 未披露 | 0.06 | 2026-09-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Oren Elmaliach | 男 | Interim Chief Financial Officer | 42 | 未披露 | 未持股 | 2026-09-18 |
| Brendan P. O'Grady | 男 | Chief Executive Officer and Director | -- | 未披露 | 未持股 | 2026-09-18 |
| Dalia Megiddo | 女 | Chief Development Officer and Chief Medical Officer and Director | 74 | 48.83万美元 | 189.41 | 2026-09-18 |
董事简历
中英对照 | 中文 | 英文- Isaac Israel
-
Isaac Israel，他曾一直担任首席执行官兼董事会成员（2013年7月以来），以及首席执行官兼董事会成员（2012年10月以来）。他曾担任BeeContact公司（原为TASE：BCNT）的创始首席执行官（从2001年到2007年）。2008年以来，他曾一直担任Uneri Capital公司（他所有的资本市场领域的咨询公司，专门从事医疗保健行业）的创始首席执行官。提供上述咨询服务时，他也担任各种私人和上市医疗保健公司的董事会成员，包括担任NextGen Biomed公司（特拉维夫证券交易所上市公司）的董事会主席。2011年以来，他也为Capital Point公司（TASE：CPTP）提供商业开发服务。
Isaac Israel is a director and serves on compensation committee and on audit and financial statement examination committee. Mr. Israel served as a member of the board of directors since October 2012, and as chief executive officer of Purple Biotech (NASDAQ: PPBT) from 2012 until 2022 and served as Acting Chief Executive Officer from March 2023 to August 2023. Since 2008, Mr. Israel has served as founding chief executive officer of Uneri Capital Ltd., a consulting firm, owned by Mr. Israel, which specializes in the healthcare sector. Mr. Israel was the founding chief executive officer of BeeContact Ltd. (formerly TASE: BCNT), from 2001 until 2007. Mr. Israel served as a member of the board of directors of vario private and public healthcare corporations, including as chairman of the board of a public healthcare corporation, NextGen Biomed Ltd. (TASE: NXGN). - Isaac Israel，他曾一直担任首席执行官兼董事会成员（2013年7月以来），以及首席执行官兼董事会成员（2012年10月以来）。他曾担任BeeContact公司（原为TASE：BCNT）的创始首席执行官（从2001年到2007年）。2008年以来，他曾一直担任Uneri Capital公司（他所有的资本市场领域的咨询公司，专门从事医疗保健行业）的创始首席执行官。提供上述咨询服务时，他也担任各种私人和上市医疗保健公司的董事会成员，包括担任NextGen Biomed公司（特拉维夫证券交易所上市公司）的董事会主席。2011年以来，他也为Capital Point公司（TASE：CPTP）提供商业开发服务。
- Isaac Israel is a director and serves on compensation committee and on audit and financial statement examination committee. Mr. Israel served as a member of the board of directors since October 2012, and as chief executive officer of Purple Biotech (NASDAQ: PPBT) from 2012 until 2022 and served as Acting Chief Executive Officer from March 2023 to August 2023. Since 2008, Mr. Israel has served as founding chief executive officer of Uneri Capital Ltd., a consulting firm, owned by Mr. Israel, which specializes in the healthcare sector. Mr. Israel was the founding chief executive officer of BeeContact Ltd. (formerly TASE: BCNT), from 2001 until 2007. Mr. Israel served as a member of the board of directors of vario private and public healthcare corporations, including as chairman of the board of a public healthcare corporation, NextGen Biomed Ltd. (TASE: NXGN).
- Udi Gilboa
-
Udi Gilboa，成立以来，他担任董事。他目前是首席执行官的特殊顾问。此外2008年2月，他联合创立Alcobra Ltd.并担任其董事。他担任其首席财务官和首席会计官知道2014年5月。从2007年到2014年，他担任Insuline Medical Ltd.（一家上市公司的股票在the Tel Aviv Stock Exchange挂牌交易）董事。他是Top Notch Capital（以色列著名生命科学投资银行）的创始人和管理合伙人。他创立许多医疗设备和制药公司。他获得Tel Aviv大学的学士学位和工商管理硕士学位。
Udi Gilboa has served as Co Founder and Executive Chairman since 2019. Since January 2012, Mr. Gilboa has been serving as a director, Senior Vice President of Operations and the Chief Financial Officer of Bioblast Pharma Ltd. (NASDAQ: ORPN). Mr. Gilboa is the founder and managing partner of TopNotch Capital Ltd., a prominent Israeli life sciences investment bank. He is also the founder of a number of medical device and pharmaceutical companies. Mr. Gilboa is Chairman of the Board of Samson NeuroSciences Ltd. Mr. Gilboa has served as a director of InsuLine Medical Ltd. (TASE: INSL) until 2014 and served, until 2010 as a director and chairman of the board of directors of Topspin Medical Ltd. Mr. Gilboa holds a Bachelor's degree and M.B.A. from Tel Aviv University. - Udi Gilboa，成立以来，他担任董事。他目前是首席执行官的特殊顾问。此外2008年2月，他联合创立Alcobra Ltd.并担任其董事。他担任其首席财务官和首席会计官知道2014年5月。从2007年到2014年，他担任Insuline Medical Ltd.（一家上市公司的股票在the Tel Aviv Stock Exchange挂牌交易）董事。他是Top Notch Capital（以色列著名生命科学投资银行）的创始人和管理合伙人。他创立许多医疗设备和制药公司。他获得Tel Aviv大学的学士学位和工商管理硕士学位。
- Udi Gilboa has served as Co Founder and Executive Chairman since 2019. Since January 2012, Mr. Gilboa has been serving as a director, Senior Vice President of Operations and the Chief Financial Officer of Bioblast Pharma Ltd. (NASDAQ: ORPN). Mr. Gilboa is the founder and managing partner of TopNotch Capital Ltd., a prominent Israeli life sciences investment bank. He is also the founder of a number of medical device and pharmaceutical companies. Mr. Gilboa is Chairman of the Board of Samson NeuroSciences Ltd. Mr. Gilboa has served as a director of InsuLine Medical Ltd. (TASE: INSL) until 2014 and served, until 2010 as a director and chairman of the board of directors of Topspin Medical Ltd. Mr. Gilboa holds a Bachelor's degree and M.B.A. from Tel Aviv University.
- David Silberman
-
David Silberman于2006年3月被任命为首席科学官和主任。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷哈大沙大学医院糖尿病部门的高级研究员。在2003年和2004年期间，Kidron博士担任Emisphere Technologies Inc.的顾问，该公司专注于开发基础广泛的专有药物输送平台。Kidron博士曾是加拿大多伦多大学医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。基德隆博士是伯尔尼·施兰格奖的获得者。
David Silberman is a director and serves on audit and financial statement examination committee. Mr. Silberman has served as the Chief Financial Officer of Compugen Ltd. (NASDAQ: CGEN) Since August 2024. Mr. Silberman previoly served as the Chief Financial Officer of Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) from May 2021 to May 2024. From April 2018 to May 2021, Mr. Silberman served as a Corporate Financial Planning and Analysis associate director and director at Teva Pharmaceutical Indtries Ltd. (NASDAQ: TEVA), a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. From 2014 to 2018, Mr. Silberman served as Global Internal Audit senior manager at Teva Pharmaceutical Indtries Ltd. From 2009 to 2014, Mr. Silberman provided internal audit and risk management services in the advisory department of Grant Thornton Fahn Kanne Control Management. From January 2009 until June 2009, Mr. Silberman worked in the audit department of KPMG, a certified public accounting firm. Mr. Silberman holds DCG and DSCG degrees from the French Ministry of Higher Study and Research and is a certified public accountant in Israel. - David Silberman于2006年3月被任命为首席科学官和主任。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷哈大沙大学医院糖尿病部门的高级研究员。在2003年和2004年期间，Kidron博士担任Emisphere Technologies Inc.的顾问，该公司专注于开发基础广泛的专有药物输送平台。Kidron博士曾是加拿大多伦多大学医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。基德隆博士是伯尔尼·施兰格奖的获得者。
- David Silberman is a director and serves on audit and financial statement examination committee. Mr. Silberman has served as the Chief Financial Officer of Compugen Ltd. (NASDAQ: CGEN) Since August 2024. Mr. Silberman previoly served as the Chief Financial Officer of Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) from May 2021 to May 2024. From April 2018 to May 2021, Mr. Silberman served as a Corporate Financial Planning and Analysis associate director and director at Teva Pharmaceutical Indtries Ltd. (NASDAQ: TEVA), a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. From 2014 to 2018, Mr. Silberman served as Global Internal Audit senior manager at Teva Pharmaceutical Indtries Ltd. From 2009 to 2014, Mr. Silberman provided internal audit and risk management services in the advisory department of Grant Thornton Fahn Kanne Control Management. From January 2009 until June 2009, Mr. Silberman worked in the audit department of KPMG, a certified public accounting firm. Mr. Silberman holds DCG and DSCG degrees from the French Ministry of Higher Study and Research and is a certified public accountant in Israel.
- Ronnie Hershman
-
Ronnie Hershman，自2020年5月起担任Nasus Pharma Ltd.董事会成员。在过去的30年里，他一直是纽约的心脏病专家。除了是一名医生，在过去的15年里，赫什曼博士也是一位活跃的天使投资人。作为天使投资人，他是Hershman Holdings LLC的创始人和主要所有者，该公司是他于2004年创立的公司。他还曾是其他几家公司的联合创始人，包括2015年8月的HealthEffect和2017年的InvestEffect。Hershman博士拥有西奈山伊坎医学院的医学博士学位和Sophie Davis CCNY生物医学教育中心的学士学位。
Ronnie Hershman has served on board of directors since May 2020 and serves on compensation committee. He has been a cardiologist in New York for the last 30 years. In addition to being a medical practitioner, for the last 15 years, Dr. Hershman has also been an active Angel Investor. As an Angel Investor, he is the Founder and Principal Owner of Hershman Holdings LLC, a company he founded in 2004. He has also been co founder of several other companies, including HealthEffect in August 2015 and InvestEffect in 2017. Dr. Hershman holds an M.D. from Icahn School of Medicine at Mount Sinai and a B.S. from Sophie Davis CCNY Center for Biomedical Education. - Ronnie Hershman，自2020年5月起担任Nasus Pharma Ltd.董事会成员。在过去的30年里，他一直是纽约的心脏病专家。除了是一名医生，在过去的15年里，赫什曼博士也是一位活跃的天使投资人。作为天使投资人，他是Hershman Holdings LLC的创始人和主要所有者，该公司是他于2004年创立的公司。他还曾是其他几家公司的联合创始人，包括2015年8月的HealthEffect和2017年的InvestEffect。Hershman博士拥有西奈山伊坎医学院的医学博士学位和Sophie Davis CCNY生物医学教育中心的学士学位。
- Ronnie Hershman has served on board of directors since May 2020 and serves on compensation committee. He has been a cardiologist in New York for the last 30 years. In addition to being a medical practitioner, for the last 15 years, Dr. Hershman has also been an active Angel Investor. As an Angel Investor, he is the Founder and Principal Owner of Hershman Holdings LLC, a company he founded in 2004. He has also been co founder of several other companies, including HealthEffect in August 2015 and InvestEffect in 2017. Dr. Hershman holds an M.D. from Icahn School of Medicine at Mount Sinai and a B.S. from Sophie Davis CCNY Center for Biomedical Education.
- Brendan P. O'Grady
-
Brendan P. O'Grady，自2024年5月起担任公司首席执行官和董事。他最近于2022年6月至2024年2月担任跨国制药公司Glenmark Pharmaceuticals Ltd.全球制剂业务的首席执行官，负责横跨六大洲的损益表，推动新产品发布，发展关键终端市场，并在表现不佳的市场中恢复盈利能力。在此之前，O'Grady先生于2021年8月至2022年6月期间担任在线医疗保健服务公司American Well Corp. dba Amwell的首席增长和商务官，负责制定和监督进入市场的战略。在此之前，他曾于2001-2021年在梯瓦制药工业有限公司担任越来越有责任的多个职位，最近于2017年11月至2021年8月担任梯瓦美国公司首席执行官兼总裁以及北美商业执行副总裁，负责领导梯瓦公司的北美业务，包括特种、仿制药和非处方药ANDA，Inc.。在此之前，奥格雷迪先生于1991年至2001年在赛诺菲担任越来越有责任的多个职位。O'Grady先生获得了纽约州立大学Geneseo（SUNY Geneseo）的管理科学学士学位、市场营销专注权以及贝克大学的工商管理硕士学位。
Brendan P. O'Grady,has served as Chief Executive Officer and a director of the Company since May 2024. He most recently served as Chief Executive Officer of the Global Formulations Business at Glenmark Pharmaceuticals Ltd., a multinational pharmaceutical company, from June 2022 to February 2024, where he was responsible for a P&L spanning six continents, driving new product launches, growing key end markets and restoring profitability in underperforming markets. Prior to that, Mr. O'Grady served as Chief Growth and Commercial Officer of American Well Corp. dba Amwell, an online healthcare services company, from August 2021 to June 2022, where he was responsible for building and overseeing a go-to-market strategy. Prior to that, he served in various positions of increasing responsibility at Teva Pharmaceutical Industries Ltd. from 2001 to 2021, most recently serving as Chief Executive Officer and President, Teva USA and Executive Vice President, North America Commercial, from November 2017 to August 2021, where he was responsible for leading Teva's North America business, including specialty, generic and over-the-counter pharmaceuticals, ANDA, Inc. Prior to that, Mr. O'Grady served in various positions of increasing responsibility at Sanofi from 1991 to 2001. Mr. O'Grady received a B.S. in Management Science, Marketing Concentration from the State University of New York at Geneseo (SUNY Geneseo) and an M.B.A. from Baker University. - Brendan P. O'Grady，自2024年5月起担任公司首席执行官和董事。他最近于2022年6月至2024年2月担任跨国制药公司Glenmark Pharmaceuticals Ltd.全球制剂业务的首席执行官，负责横跨六大洲的损益表，推动新产品发布，发展关键终端市场，并在表现不佳的市场中恢复盈利能力。在此之前，O'Grady先生于2021年8月至2022年6月期间担任在线医疗保健服务公司American Well Corp. dba Amwell的首席增长和商务官，负责制定和监督进入市场的战略。在此之前，他曾于2001-2021年在梯瓦制药工业有限公司担任越来越有责任的多个职位，最近于2017年11月至2021年8月担任梯瓦美国公司首席执行官兼总裁以及北美商业执行副总裁，负责领导梯瓦公司的北美业务，包括特种、仿制药和非处方药ANDA，Inc.。在此之前，奥格雷迪先生于1991年至2001年在赛诺菲担任越来越有责任的多个职位。O'Grady先生获得了纽约州立大学Geneseo（SUNY Geneseo）的管理科学学士学位、市场营销专注权以及贝克大学的工商管理硕士学位。
- Brendan P. O'Grady,has served as Chief Executive Officer and a director of the Company since May 2024. He most recently served as Chief Executive Officer of the Global Formulations Business at Glenmark Pharmaceuticals Ltd., a multinational pharmaceutical company, from June 2022 to February 2024, where he was responsible for a P&L spanning six continents, driving new product launches, growing key end markets and restoring profitability in underperforming markets. Prior to that, Mr. O'Grady served as Chief Growth and Commercial Officer of American Well Corp. dba Amwell, an online healthcare services company, from August 2021 to June 2022, where he was responsible for building and overseeing a go-to-market strategy. Prior to that, he served in various positions of increasing responsibility at Teva Pharmaceutical Industries Ltd. from 2001 to 2021, most recently serving as Chief Executive Officer and President, Teva USA and Executive Vice President, North America Commercial, from November 2017 to August 2021, where he was responsible for leading Teva's North America business, including specialty, generic and over-the-counter pharmaceuticals, ANDA, Inc. Prior to that, Mr. O'Grady served in various positions of increasing responsibility at Sanofi from 1991 to 2001. Mr. O'Grady received a B.S. in Management Science, Marketing Concentration from the State University of New York at Geneseo (SUNY Geneseo) and an M.B.A. from Baker University.
- Dalia Megiddo
-
Dalia Megiddo，在2008年2月共同创办了本公司，担任董事一职。她是家庭医学领域的企业家和医生。自2000年以来，她一直担任InnoMed合资公司的总经理，这是一家专注于生命科学的以色列风险投资基金经理。从2006年到2010年，她是7 Health Ventures的总经理，一个以色列风险投资基金。她也是多家生命科学公司的创始人。她现任Bioblast有限公司和Humavox有限公司的董事；并曾经担任Tulip医疗设备有限公司、Chiasma公司和AngioScore有限公司的董事。她持有希伯来大学哈达萨医学院的医学博士学位和凯洛格纳蒂商学院的工商管理硕士学位。
Dalia Megiddo is one of Co Founders and served as director since May 2019. She has also served as Chief Development Officer and Chief Medical Officer since June 2019. Dr. Megiddo also served as Chief Executive Officer from March 2020 to January 2025. She has founded and served as management or a director for multiple biopharma and medtech companies, including Chiasma Inc. (NASDAQ: CHMA) from 2002 to 2008 as co founder and director; Medingo Ltd. (sold to Roche Holding AG) from 2005 to 2007 as co founder and director; Alcobra Pharmaceuticals Ltd. (NASDAQ: ADHD) from 2008 to 2013 as co founder and director; and Bioblast Pharma Ltd. (NASDAQ: ORPN) from February 2012 through its public offering in February 2015 as CEO and director from February 2012 to March 2019. Dr. Megiddo managed two venture capital funds: 7 Health Ventures from 2006 through 2010 and InnoMed Ventures, since 2000. Dr Megiddo has been involved in the Life Science Venture Capital Indtry since 1999 and is ll recognized as one of the leaders in the healthcare investment and entrepreneurial community both in Israel and internationally. She is a frequent speaker at local and international meetings and served as a board member at Given Imaging Ltd. (NASDAQ: GIVN), Elron Ventures Ltd. (NASDAQ: ELRN), Alcobra, and Bioblast. Dr. Megiddo is member of the scientific investment advisory boards to several academic institutes in Israel including the Technion and Tel Aviv University. Dr. Megiddo holds an MBA from Kellogg Recanati School of Biness, and teaches at vario entrepreneurial programs in Israeli universities. She completed her medical studies at the Hebrew University's Hadassah Medical School and a specialty program in Family Medicine. After spending a few years as a faculty member in the Family Medicine department at the Hebrew University in Jeralem, Dr. Megiddo founded and sold two successful binesses in the medical field: The Jnal Club Israel's leading provider of Continuing Medical Education for physicians, and Academia Medica – a medical multimedia developer and worldwide distributor for Continuing Medical Education programs for physicians. - Dalia Megiddo，在2008年2月共同创办了本公司，担任董事一职。她是家庭医学领域的企业家和医生。自2000年以来，她一直担任InnoMed合资公司的总经理，这是一家专注于生命科学的以色列风险投资基金经理。从2006年到2010年，她是7 Health Ventures的总经理，一个以色列风险投资基金。她也是多家生命科学公司的创始人。她现任Bioblast有限公司和Humavox有限公司的董事；并曾经担任Tulip医疗设备有限公司、Chiasma公司和AngioScore有限公司的董事。她持有希伯来大学哈达萨医学院的医学博士学位和凯洛格纳蒂商学院的工商管理硕士学位。
- Dalia Megiddo is one of Co Founders and served as director since May 2019. She has also served as Chief Development Officer and Chief Medical Officer since June 2019. Dr. Megiddo also served as Chief Executive Officer from March 2020 to January 2025. She has founded and served as management or a director for multiple biopharma and medtech companies, including Chiasma Inc. (NASDAQ: CHMA) from 2002 to 2008 as co founder and director; Medingo Ltd. (sold to Roche Holding AG) from 2005 to 2007 as co founder and director; Alcobra Pharmaceuticals Ltd. (NASDAQ: ADHD) from 2008 to 2013 as co founder and director; and Bioblast Pharma Ltd. (NASDAQ: ORPN) from February 2012 through its public offering in February 2015 as CEO and director from February 2012 to March 2019. Dr. Megiddo managed two venture capital funds: 7 Health Ventures from 2006 through 2010 and InnoMed Ventures, since 2000. Dr Megiddo has been involved in the Life Science Venture Capital Indtry since 1999 and is ll recognized as one of the leaders in the healthcare investment and entrepreneurial community both in Israel and internationally. She is a frequent speaker at local and international meetings and served as a board member at Given Imaging Ltd. (NASDAQ: GIVN), Elron Ventures Ltd. (NASDAQ: ELRN), Alcobra, and Bioblast. Dr. Megiddo is member of the scientific investment advisory boards to several academic institutes in Israel including the Technion and Tel Aviv University. Dr. Megiddo holds an MBA from Kellogg Recanati School of Biness, and teaches at vario entrepreneurial programs in Israeli universities. She completed her medical studies at the Hebrew University's Hadassah Medical School and a specialty program in Family Medicine. After spending a few years as a faculty member in the Family Medicine department at the Hebrew University in Jeralem, Dr. Megiddo founded and sold two successful binesses in the medical field: The Jnal Club Israel's leading provider of Continuing Medical Education for physicians, and Academia Medica – a medical multimedia developer and worldwide distributor for Continuing Medical Education programs for physicians.
- Sharon Shacham
-
Sharon Shacham，2008年成立了Karyopharm公司（Karyopharm），从2013年12月开始担任公司总裁，从2010年10月开始担任首席科学官。她从2012年12月到2013年12月担任公司研究发展总裁，从2010年10月到2012年12月担任公司研究发展主任，从2010年10月到2011年1月担任公司总裁和首席执行官。她成立该公司专注于发现和发展核溢出的小分子抑制剂，也从一开始就领导了公司的科技进步。她计算药物开发的算法形成了公司药物发明技术基础和优化平台的重要组成部分，优化平台用于Selinexor 的发明，这是公司的领导药物。她是科技顾问委员会的联席主席。在成立Karyopharm公司（Karyopharm）之前，从2000年7月到2009年4月，她是Epix制药公司（Epix Pharmaceuticals, Inc）药物发展高级副总裁，该公司2009年在马塞诸塞州法律下通过向债权人分配实行了清算程序；也是Predix制药公司（Predix Pharmaceuticals Inc.）算法和程序主任，该公司2006年被Epix制药公司（Epix Pharmaceuticals, Inc）并购，在那里她领导了对G蛋白偶联受体模型、计算化学、先导化合物优化、临床试验发展的研究。她获得化学学士学位，在Tel Aviv大学获得哲学博士和工商管理硕士。
Sharon Shacham is a director and serves on compensation committee and on audit and financial statement examination committee. Dr. Shacham has served as a director at Acrivon Theraputics, Inc. (NASDAQ: ACRV) since May 2021, non executive director at exteRNA since August 2024 and director of Protai Therapeutics since January 2023. Dr. Shacham co founded Karyopharm (NASDAQ: KPTI) in 2008 and served as its Chief Scientific Officer and head of Research and Development from 2010 until May 2022, and as President from 2013 until May 2021. Dr. Shacham has previoly led scientific and clinical work that led to the discovery, development and regulatory approval of first in class drug candidates. Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, where she led the company's efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials. Dr. Shacham holds a B.S. in chemistry, a Ph.D. in biophysical chemistry, and an M.B.A. from Tel Aviv University. - Sharon Shacham，2008年成立了Karyopharm公司（Karyopharm），从2013年12月开始担任公司总裁，从2010年10月开始担任首席科学官。她从2012年12月到2013年12月担任公司研究发展总裁，从2010年10月到2012年12月担任公司研究发展主任，从2010年10月到2011年1月担任公司总裁和首席执行官。她成立该公司专注于发现和发展核溢出的小分子抑制剂，也从一开始就领导了公司的科技进步。她计算药物开发的算法形成了公司药物发明技术基础和优化平台的重要组成部分，优化平台用于Selinexor 的发明，这是公司的领导药物。她是科技顾问委员会的联席主席。在成立Karyopharm公司（Karyopharm）之前，从2000年7月到2009年4月，她是Epix制药公司（Epix Pharmaceuticals, Inc）药物发展高级副总裁，该公司2009年在马塞诸塞州法律下通过向债权人分配实行了清算程序；也是Predix制药公司（Predix Pharmaceuticals Inc.）算法和程序主任，该公司2006年被Epix制药公司（Epix Pharmaceuticals, Inc）并购，在那里她领导了对G蛋白偶联受体模型、计算化学、先导化合物优化、临床试验发展的研究。她获得化学学士学位，在Tel Aviv大学获得哲学博士和工商管理硕士。
- Sharon Shacham is a director and serves on compensation committee and on audit and financial statement examination committee. Dr. Shacham has served as a director at Acrivon Theraputics, Inc. (NASDAQ: ACRV) since May 2021, non executive director at exteRNA since August 2024 and director of Protai Therapeutics since January 2023. Dr. Shacham co founded Karyopharm (NASDAQ: KPTI) in 2008 and served as its Chief Scientific Officer and head of Research and Development from 2010 until May 2022, and as President from 2013 until May 2021. Dr. Shacham has previoly led scientific and clinical work that led to the discovery, development and regulatory approval of first in class drug candidates. Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, where she led the company's efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials. Dr. Shacham holds a B.S. in chemistry, a Ph.D. in biophysical chemistry, and an M.B.A. from Tel Aviv University.
高管简历
中英对照 | 中文 | 英文- Oren Elmaliach
Oren Elmaliach，自2019年起担任Nasus Pharma Ltd.财务总监。2015年9月，Oren Elmaliach创立了Accounting Team Ltd.，这是一家为在以色列和国外交易的上市公司提供财务咨询和服务的公司，此后一直担任客户经理。2017年2月至今，Elmaliach先生担任Ayala Pharmaceuticals Inc.（NASDAQ：AYLA）的控制人，自2022年2月起担任Igentify的首席财务官。此外，自2015年9月起，Elmaliach先生担任LG Electronics Israel的以色列当局报告官，并自2015年9月起担任Chiasma Inc.（NASDAQ：CHMA）的当地财务报告顾问。从2017年5月起，Oren担任MySize，Inc（NASDAQ：MYSZ）审计委员会主席。2011年7月至2015年8月，Elmaliach先生担任CFO Director Ltd.的注册会计师、财务总监，并于2010年6月至2011年7月担任RSM International Limited的风险管理顾问。Elmaliach先生拥有以色列特拉维夫大学会计学/经济学文学学士学位和金融/会计学硕士学位。他是以色列的持牌注册会计师。
Oren Elmaliach,has served as Director of Finance since 2019. In September 2015, Oren Elmaliach founded Accounting Team Ltd., a financial consultancy and service provider to public companies traded in Israel and abroad, and has acted as Account Manager since then. Since February 2017, Mr. Elmaliach has served as controller of Ayala Pharmaceuticals Inc. (NASDAQ: AYLA), and since Februray 2022 he has served as Chief Financial Officer of Igentify. In addition, since September 2015, Mr. Elmaliach has served as an Israel Authorities Reporting Officer of LG Electronics Israel and since September 2015 he has served as Local Financial Report Consultant of Chiasma Inc. (NASDAQ: CHMA). From May 2017, Oren has served as chairman of the audit committee of Mysize, Inc (NASDAQ: MYSZ). From July 2011 until August 2015, Mr. Elmaliach served as CPA, Financial Director of CFO Director Ltd. and from June 2010 until July 2011 he served as Risk Management Consultant of RSM International Limited. Mr. Elmaliach holds a Bachelor of Arts in Accounting/Economics and a Msc. in Finance/Accounting from Tel Aviv University, Israel. He is a licensed Certified Public Accountant in Israel.- Oren Elmaliach，自2019年起担任Nasus Pharma Ltd.财务总监。2015年9月，Oren Elmaliach创立了Accounting Team Ltd.，这是一家为在以色列和国外交易的上市公司提供财务咨询和服务的公司，此后一直担任客户经理。2017年2月至今，Elmaliach先生担任Ayala Pharmaceuticals Inc.（NASDAQ：AYLA）的控制人，自2022年2月起担任Igentify的首席财务官。此外，自2015年9月起，Elmaliach先生担任LG Electronics Israel的以色列当局报告官，并自2015年9月起担任Chiasma Inc.（NASDAQ：CHMA）的当地财务报告顾问。从2017年5月起，Oren担任MySize，Inc（NASDAQ：MYSZ）审计委员会主席。2011年7月至2015年8月，Elmaliach先生担任CFO Director Ltd.的注册会计师、财务总监，并于2010年6月至2011年7月担任RSM International Limited的风险管理顾问。Elmaliach先生拥有以色列特拉维夫大学会计学/经济学文学学士学位和金融/会计学硕士学位。他是以色列的持牌注册会计师。
- Oren Elmaliach,has served as Director of Finance since 2019. In September 2015, Oren Elmaliach founded Accounting Team Ltd., a financial consultancy and service provider to public companies traded in Israel and abroad, and has acted as Account Manager since then. Since February 2017, Mr. Elmaliach has served as controller of Ayala Pharmaceuticals Inc. (NASDAQ: AYLA), and since Februray 2022 he has served as Chief Financial Officer of Igentify. In addition, since September 2015, Mr. Elmaliach has served as an Israel Authorities Reporting Officer of LG Electronics Israel and since September 2015 he has served as Local Financial Report Consultant of Chiasma Inc. (NASDAQ: CHMA). From May 2017, Oren has served as chairman of the audit committee of Mysize, Inc (NASDAQ: MYSZ). From July 2011 until August 2015, Mr. Elmaliach served as CPA, Financial Director of CFO Director Ltd. and from June 2010 until July 2011 he served as Risk Management Consultant of RSM International Limited. Mr. Elmaliach holds a Bachelor of Arts in Accounting/Economics and a Msc. in Finance/Accounting from Tel Aviv University, Israel. He is a licensed Certified Public Accountant in Israel.
- Brendan P. O'Grady
Brendan P. O'Grady，自2024年5月起担任公司首席执行官和董事。他最近于2022年6月至2024年2月担任跨国制药公司Glenmark Pharmaceuticals Ltd.全球制剂业务的首席执行官，负责横跨六大洲的损益表，推动新产品发布，发展关键终端市场，并在表现不佳的市场中恢复盈利能力。在此之前，O'Grady先生于2021年8月至2022年6月期间担任在线医疗保健服务公司American Well Corp. dba Amwell的首席增长和商务官，负责制定和监督进入市场的战略。在此之前，他曾于2001-2021年在梯瓦制药工业有限公司担任越来越有责任的多个职位，最近于2017年11月至2021年8月担任梯瓦美国公司首席执行官兼总裁以及北美商业执行副总裁，负责领导梯瓦公司的北美业务，包括特种、仿制药和非处方药ANDA，Inc.。在此之前，奥格雷迪先生于1991年至2001年在赛诺菲担任越来越有责任的多个职位。O'Grady先生获得了纽约州立大学Geneseo（SUNY Geneseo）的管理科学学士学位、市场营销专注权以及贝克大学的工商管理硕士学位。
Brendan P. O'Grady,has served as Chief Executive Officer and a director of the Company since May 2024. He most recently served as Chief Executive Officer of the Global Formulations Business at Glenmark Pharmaceuticals Ltd., a multinational pharmaceutical company, from June 2022 to February 2024, where he was responsible for a P&L spanning six continents, driving new product launches, growing key end markets and restoring profitability in underperforming markets. Prior to that, Mr. O'Grady served as Chief Growth and Commercial Officer of American Well Corp. dba Amwell, an online healthcare services company, from August 2021 to June 2022, where he was responsible for building and overseeing a go-to-market strategy. Prior to that, he served in various positions of increasing responsibility at Teva Pharmaceutical Industries Ltd. from 2001 to 2021, most recently serving as Chief Executive Officer and President, Teva USA and Executive Vice President, North America Commercial, from November 2017 to August 2021, where he was responsible for leading Teva's North America business, including specialty, generic and over-the-counter pharmaceuticals, ANDA, Inc. Prior to that, Mr. O'Grady served in various positions of increasing responsibility at Sanofi from 1991 to 2001. Mr. O'Grady received a B.S. in Management Science, Marketing Concentration from the State University of New York at Geneseo (SUNY Geneseo) and an M.B.A. from Baker University.- Brendan P. O'Grady，自2024年5月起担任公司首席执行官和董事。他最近于2022年6月至2024年2月担任跨国制药公司Glenmark Pharmaceuticals Ltd.全球制剂业务的首席执行官，负责横跨六大洲的损益表，推动新产品发布，发展关键终端市场，并在表现不佳的市场中恢复盈利能力。在此之前，O'Grady先生于2021年8月至2022年6月期间担任在线医疗保健服务公司American Well Corp. dba Amwell的首席增长和商务官，负责制定和监督进入市场的战略。在此之前，他曾于2001-2021年在梯瓦制药工业有限公司担任越来越有责任的多个职位，最近于2017年11月至2021年8月担任梯瓦美国公司首席执行官兼总裁以及北美商业执行副总裁，负责领导梯瓦公司的北美业务，包括特种、仿制药和非处方药ANDA，Inc.。在此之前，奥格雷迪先生于1991年至2001年在赛诺菲担任越来越有责任的多个职位。O'Grady先生获得了纽约州立大学Geneseo（SUNY Geneseo）的管理科学学士学位、市场营销专注权以及贝克大学的工商管理硕士学位。
- Brendan P. O'Grady,has served as Chief Executive Officer and a director of the Company since May 2024. He most recently served as Chief Executive Officer of the Global Formulations Business at Glenmark Pharmaceuticals Ltd., a multinational pharmaceutical company, from June 2022 to February 2024, where he was responsible for a P&L spanning six continents, driving new product launches, growing key end markets and restoring profitability in underperforming markets. Prior to that, Mr. O'Grady served as Chief Growth and Commercial Officer of American Well Corp. dba Amwell, an online healthcare services company, from August 2021 to June 2022, where he was responsible for building and overseeing a go-to-market strategy. Prior to that, he served in various positions of increasing responsibility at Teva Pharmaceutical Industries Ltd. from 2001 to 2021, most recently serving as Chief Executive Officer and President, Teva USA and Executive Vice President, North America Commercial, from November 2017 to August 2021, where he was responsible for leading Teva's North America business, including specialty, generic and over-the-counter pharmaceuticals, ANDA, Inc. Prior to that, Mr. O'Grady served in various positions of increasing responsibility at Sanofi from 1991 to 2001. Mr. O'Grady received a B.S. in Management Science, Marketing Concentration from the State University of New York at Geneseo (SUNY Geneseo) and an M.B.A. from Baker University.
- Dalia Megiddo
Dalia Megiddo，在2008年2月共同创办了本公司，担任董事一职。她是家庭医学领域的企业家和医生。自2000年以来，她一直担任InnoMed合资公司的总经理，这是一家专注于生命科学的以色列风险投资基金经理。从2006年到2010年，她是7 Health Ventures的总经理，一个以色列风险投资基金。她也是多家生命科学公司的创始人。她现任Bioblast有限公司和Humavox有限公司的董事；并曾经担任Tulip医疗设备有限公司、Chiasma公司和AngioScore有限公司的董事。她持有希伯来大学哈达萨医学院的医学博士学位和凯洛格纳蒂商学院的工商管理硕士学位。
Dalia Megiddo is one of Co Founders and served as director since May 2019. She has also served as Chief Development Officer and Chief Medical Officer since June 2019. Dr. Megiddo also served as Chief Executive Officer from March 2020 to January 2025. She has founded and served as management or a director for multiple biopharma and medtech companies, including Chiasma Inc. (NASDAQ: CHMA) from 2002 to 2008 as co founder and director; Medingo Ltd. (sold to Roche Holding AG) from 2005 to 2007 as co founder and director; Alcobra Pharmaceuticals Ltd. (NASDAQ: ADHD) from 2008 to 2013 as co founder and director; and Bioblast Pharma Ltd. (NASDAQ: ORPN) from February 2012 through its public offering in February 2015 as CEO and director from February 2012 to March 2019. Dr. Megiddo managed two venture capital funds: 7 Health Ventures from 2006 through 2010 and InnoMed Ventures, since 2000. Dr Megiddo has been involved in the Life Science Venture Capital Indtry since 1999 and is ll recognized as one of the leaders in the healthcare investment and entrepreneurial community both in Israel and internationally. She is a frequent speaker at local and international meetings and served as a board member at Given Imaging Ltd. (NASDAQ: GIVN), Elron Ventures Ltd. (NASDAQ: ELRN), Alcobra, and Bioblast. Dr. Megiddo is member of the scientific investment advisory boards to several academic institutes in Israel including the Technion and Tel Aviv University. Dr. Megiddo holds an MBA from Kellogg Recanati School of Biness, and teaches at vario entrepreneurial programs in Israeli universities. She completed her medical studies at the Hebrew University's Hadassah Medical School and a specialty program in Family Medicine. After spending a few years as a faculty member in the Family Medicine department at the Hebrew University in Jeralem, Dr. Megiddo founded and sold two successful binesses in the medical field: The Jnal Club Israel's leading provider of Continuing Medical Education for physicians, and Academia Medica – a medical multimedia developer and worldwide distributor for Continuing Medical Education programs for physicians.- Dalia Megiddo，在2008年2月共同创办了本公司，担任董事一职。她是家庭医学领域的企业家和医生。自2000年以来，她一直担任InnoMed合资公司的总经理，这是一家专注于生命科学的以色列风险投资基金经理。从2006年到2010年，她是7 Health Ventures的总经理，一个以色列风险投资基金。她也是多家生命科学公司的创始人。她现任Bioblast有限公司和Humavox有限公司的董事；并曾经担任Tulip医疗设备有限公司、Chiasma公司和AngioScore有限公司的董事。她持有希伯来大学哈达萨医学院的医学博士学位和凯洛格纳蒂商学院的工商管理硕士学位。
- Dalia Megiddo is one of Co Founders and served as director since May 2019. She has also served as Chief Development Officer and Chief Medical Officer since June 2019. Dr. Megiddo also served as Chief Executive Officer from March 2020 to January 2025. She has founded and served as management or a director for multiple biopharma and medtech companies, including Chiasma Inc. (NASDAQ: CHMA) from 2002 to 2008 as co founder and director; Medingo Ltd. (sold to Roche Holding AG) from 2005 to 2007 as co founder and director; Alcobra Pharmaceuticals Ltd. (NASDAQ: ADHD) from 2008 to 2013 as co founder and director; and Bioblast Pharma Ltd. (NASDAQ: ORPN) from February 2012 through its public offering in February 2015 as CEO and director from February 2012 to March 2019. Dr. Megiddo managed two venture capital funds: 7 Health Ventures from 2006 through 2010 and InnoMed Ventures, since 2000. Dr Megiddo has been involved in the Life Science Venture Capital Indtry since 1999 and is ll recognized as one of the leaders in the healthcare investment and entrepreneurial community both in Israel and internationally. She is a frequent speaker at local and international meetings and served as a board member at Given Imaging Ltd. (NASDAQ: GIVN), Elron Ventures Ltd. (NASDAQ: ELRN), Alcobra, and Bioblast. Dr. Megiddo is member of the scientific investment advisory boards to several academic institutes in Israel including the Technion and Tel Aviv University. Dr. Megiddo holds an MBA from Kellogg Recanati School of Biness, and teaches at vario entrepreneurial programs in Israeli universities. She completed her medical studies at the Hebrew University's Hadassah Medical School and a specialty program in Family Medicine. After spending a few years as a faculty member in the Family Medicine department at the Hebrew University in Jeralem, Dr. Megiddo founded and sold two successful binesses in the medical field: The Jnal Club Israel's leading provider of Continuing Medical Education for physicians, and Academia Medica – a medical multimedia developer and worldwide distributor for Continuing Medical Education programs for physicians.